Literature DB >> 29574434

Herpes zoster ophthalmicus evolving into headache characterised as hemicrania continua.

Sanjay Prakash1, Ankit Dave1, Hemant Joshi1.   

Abstract

Postherpetic neuralgia (PHN) is the most common chronic complication of herpes zoster infection. However, a few patients may develop different types of pain after herpetic lesions. We are reporting two patients who developed postherpetic hemicrania continua (HC). Case 1: a 54-year-old woman had a 10-month history of continuous left-sided pain with superimposed exacerbations. The pain started with the onset of herpetic lesions in the ophthalmic division. The lesions subsided in a few weeks. However, the pain persisted and it responded exclusively to indomethacin. Case 2: a 61-year-old woman developed clinical features pertinent to PHN. However, later on, the pattern and associated clinical features changed. The patient fulfilled the criteria of HC and showed a complete response to indomethacin. We suggest that every patient with PHN should be asked for cranial autonomic features and a trial of indomethacin should be given in refractory herpes zoster neuropathy. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  headache (including migraines); pain (neurology)

Mesh:

Substances:

Year:  2018        PMID: 29574434      PMCID: PMC5878258          DOI: 10.1136/bcr-2018-224235

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

Review 1.  Hemicrania Continua: a Clinical Perspective on Diagnosis and Management.

Authors:  Amit Mehta; Priyanka Chilakamarri; Adeel Zubair; Deena E Kuruvilla
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-17       Impact factor: 5.081

2.  Mary Shelley's migraines and fatal stroke: some observations on their primary cause.

Authors:  Francesco Maria Galassi; Elena Varotto; Andreas Nerlich; Raffaella Bianucci
Journal:  Acta Biomed       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.